India’s Laurus Labs is aiming to supply antiretrovirals through South Africa’s public tender system after agreeing a deal to buy Aspen Pharmacare’s Phekolong Pharmaceuticals subsidiary.

Biocon has joined the march of Indian firms into China, tying up with Chinese firm CMS to sell three generic formulations in the world’s second-largest drug market.

A year after their initial tie-up, US plant-based tech firm iBio Inc. and China’s CC-Pharming Ltd are expanding their collaboration on developing a plant-derived bio-better rituximab candidate for the Chinese market.

Zentiva has struck a deal to acquire a manufacturing site in Ankleshwar, India, from its former parent company Sanofi.

Samsung Bioepis has entered a fifth continent by launching its Brenzys etanercept biosimilar in Brazil, as part of global expansion plans for the business.

Strides Pharma Science has acquired a majority stake in Swiss generics firm Fairmed Healthcare in a move to bolster its presence in central Europe. The acquisition marks the latest in a string of transactions by the Indian firm.

Lupin is staring at stretched launch timelines in the US for its generic ProAir following a Complete Response Letter, but the company maintains that its application has progressed and the market opportunity for the product remains attractive.

A body supported by biologic originators has attacked British Columbia’s move to switch Crohn’s and colitis patient to infliximab biosimilars, even though the resulting savings will be invested in patient care.

By weakening ways to challenge drug patent thickets, proposed legislation to reform US patent law would extend brand monopolies and increase spending on medicines, the Association for Accessible Medicines is warning.

Final guidance published by the US FDA on citizen petitions seeks to put an end to the originator ‘shenanigans’ of using petitions to delay competition.

More than 50 product-specific guidances for generic drug development have been published by the FDA, comprising 34 new and 19 revised documents.

Interchangeability should be seen as a scientific concept rather than a therapeutic choice of biosimilar or reference biologic, Spanish physicians argue in a journal article.

Lupin is staring at stretched launch timelines in the US for its generic ProAir following a Complete Response Letter, but the company maintains that its application has progressed and the market opportunity for the product remains attractive.

Shortlists for each of the 14 categories in the Global Generics & Biosimilars Awards 2019 have been announced, after our panel of expert judges considered almost 100 entries.

By weakening ways to challenge drug patent thickets, proposed legislation to reform US patent law would extend brand monopolies and increase spending on medicines, the Association for Accessible Medicines is warning.

A body supported by biologic originators has attacked British Columbia’s move to switch Crohn’s and colitis patient to infliximab biosimilars, even though the resulting savings will be invested in patient care.

Shortlists for each of the 14 categories in the Global Generics & Biosimilars Awards 2019 have been announced, after our panel of expert judges considered almost 100 entries.

By weakening ways to challenge drug patent thickets, proposed legislation to reform US patent law would extend brand monopolies and increase spending on medicines, the Association for Accessible Medicines is warning.

Shortlists for each of the 14 categories in the Global Generics & Biosimilars Awards 2019 have been announced, after our panel of expert judges considered almost 100 entries.

Fixed-dose polypills containing commonly available generic cardiovascular agents could cut risks in low-income populations within the US, a randomized clinical trial suggests.

Judges for the Global Generics & Biosimilars Awards 2019 are weighing a record number of entries this year, ahead of the shortlists for each of the 14 categories being announced on 20 September.